KOJI KIMURA

Profile Information

Affiliation: School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Degree: 薬学修士(東京薬科大学)

J-GLOBAL ID: 201901006149164921
researchmap Member ID: B000364829

Research Interests

医療薬学

Research Areas

Research History

- Present

School of Pharmacy, Tokyo University of Pharmacy and Life Sciences

Education

Tokyo University of Pharmacy and Life Sciences

Awards

Dec, 2021

Excellent Presentation Award, The 42nd Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics

Papers

Predictor of primary response to antitumor necrosis factor-α therapy for inflammatory bowel disease: a single-center observational study.

Atsushi Yoshida, Koji Kimura, Toshio Morizane, Fumiaki Ueno

European journal of gastroenterology & hepatology, 34(6) 640-645, Jun 1, 2022 Peer-reviewedCorresponding author
Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling

Koji Kimura, Atsushi Yoshida, Fumihiko Katagiri, Risa Takayanagi, Yasuhiko Yamada

European Journal of Pharmaceutical Sciences, 150 105317-105317, Jul, 2020 Peer-reviewedLead authorCorresponding author
Comparisons of Usual Dose of Pharmaceutical Products Used in Japan and United States: Can Differences Be Explained by Pharmacokinetics Alone?

Takayanagi R, Endo Y, Kimura K, Yamada Y

Therapeutic innovation & regulatory science, 53(5) 684-690, Sep, 2019 Peer-reviewedCorresponding author
Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.

Kimura K, Yoshida A, Katagiri F, Takayanagi R, Yamada Y

Biopharmaceutics & drug disposition, 40(7) 250-261, Jul, 2019 Peer-reviewedLead authorCorresponding author
Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease.

Kimura K, Yoshida A, Takayanagi R, Yamada Y

Biopharmaceutics & drug disposition, 39(6) 283-288, Jun, 2018 Peer-reviewedLead authorCorresponding author
Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.

Takayanagi R, Uchida T, Kimura K, Yamada Y

Biological & pharmaceutical bulletin, 41(2) 153-157, 2018 Peer-reviewedCorresponding author
Method for prediction of efficacy of sugammadex administered to recover from rocuronium-induced neuromuscular blockade in gynecological laparoscopic surgery cases

Koji Kimura, Kazuya Omura, Tetsuya Hoshino, Hiroyuki Takahashi, Masaharu Imaura, Yasuhiko Yamada

Biological and Pharmaceutical Bulletin, 41(3) 312-318, 2018 Peer-reviewedLead authorCorresponding author
Effects of FCGRIIIa-158V/F polymorphism on antibody-dependent cellular cytotoxicity activity of adalimumab

Koji Kimura, Daigo Kobayashi, Saori Hatoyama, Mizuki Yamamoto, Risa Takayanagi, Yasuhiko Yamada

APMIS, 125(12) 1102-1107, Dec, 2017 Peer-reviewedLead authorCorresponding author
Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment

Koji Kimura, Risa Takayanagi, Tomoki Fukushima, Yasuhiko Yamada

MEDICAL ONCOLOGY, 34(10) 178, Oct, 2017 Peer-reviewedLead authorCorresponding author
Evaluation of the Effects of Pharmacist Intervention for Adverse Drug Reaction Detection and Exacerbation Avoidance

Masaharu Imaura, Takeshi Yamaya, Nozomi Uehara, Narutoshi Mano, Satoshi Nagase, Koji Kimura, Hiroshi Kanno, Yasuhiko Yamada

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 137(6) 767-774, Jun, 2017 Peer-reviewedCorresponding author
Analysis of Clinical Efficacy and Adverse Effects of beta-Blocking Agents Used Clinically for Chronic Heart Failure

Risa Takayanagi, Kaori Fujito, Koji Kimura, Yasuhiko Yamada

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(6) 837-843, Jun, 2017 Peer-reviewedCorresponding author
Evaluation of drug efficacy of DPP-4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics

Risa Takayanagi, Takumi Uchida, Koji Kimura, Yasuhiko Yamada

BIOPHARMACEUTICS & DRUG DISPOSITION, 38(4) 273-279, May, 2017 Peer-reviewedCorresponding author
Effects of tumor necrosis factor-857C/T polymorphism on the expression of tumor necrosis factor

Koji Kimura, Risa Takayanagi, Haruko Yokoyama, Yasuhiko Yamada

APMIS, 124(8) 669-674, Aug, 2016 Peer-reviewedLead authorCorresponding author
Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model

Koji Kimura, Naomi Kanehira, Risa Takayanagi, Hideto Minohara, Masato Homma, Yasuhiko Yamada

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 39(5) 705-711, May, 2016 Peer-reviewedLead authorCorresponding author
Evaluation of clinical bradycardiac effect and respiratory adverse effect of beta-blocking agents in coronary computed tomography angiography based on theoretical analysis

Kaori Fujito, Risa Takayanagi, Koji Kimura, Haruko Yokoyama, Yasuhiko Yamada

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 41(2) 157-167, Apr, 2016 Peer-reviewed
Theory-based Analysis of the Anti-inflammatory Effect of TNF Inhibitors on Rheumatoid Arthritis

Koji Kimura, Risa Takayanagi, Haruko Yokoyama, Yasuhiko Yamada

DRUG METABOLISM AND PHARMACOKINETICS, 29(3) 272-277, Jun, 2014 Peer-reviewedLead author
Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis

Koji Kimura, Risa Takayanagi, Haruko Yokoyama, Yasuhiko Yamada

RHEUMATOLOGY INTERNATIONAL, 32(1) 145-150, Jan, 2012 Peer-reviewedLead author

Misc.

抗凝固療法の適正化を志向した直接第Xa因子阻害薬の血中濃度簡易測定法の開発

片桐文彦, 近藤海斗, 大和田悠乃, 木村耕二, 高柳理早, 山田安彦

日本医薬品情報学会総会・学術大会講演要旨集, 25th (Web), 2023
汎発性血管内血液凝固症治療薬トロンボモデュリンアルファの効果・副作用に関する理論的解析

片桐文彦, 田中(鳩山)紗緒里, 坂本麻衣子, 今浦将治, 今浦将治, 木村耕二, 高柳理早, 山田安彦

日本臨床薬理学会学術総会抄録集(Web), 43rd, 2022
PK/PD理論に基づいた炎症性腸疾患の治療におけるインフリキシマブの適正使用に関する研究

木村耕二, 吉田篤史

日本臨床薬理学会学術総会抄録集(Web), 42nd, 2021
マウスラミニンα3鎖N末端領域の生物活性部位の同定

片桐文彦, 橋詰満奈, 緑川夏紀, 平岡智美, 木村耕二, 高柳理早, 野水基義, 山田安彦

日本薬学会年会要旨集(CD-ROM), 139th(3) ROMBUNNO.22PO‐pm215-139, 2019
糖尿病診断における血漿中キスペプチン濃度のバイオマーカーとしての有用性評価

片桐文彦, 小谷仁人, 木村耕二, 高柳理早, 山田安彦

日本医療薬学会年会講演要旨集(Web), 28, 2018
関節リウマチに対するトシリズマブの薬物動態学的および薬力学的モデル解析

菊池晟広, 木村耕二, 高柳理早, 山田安彦

日本薬学会年会要旨集(CD-ROM), 138th ROMBUNNO.28PA‐am115, 2018
炎症性腸疾患に対するインフリキシマブの治療効果の予測に関する検討

木村耕二, 吉田篤史, 高柳理早, 山田安彦

臨床薬理, 48(Supplement) S258, Nov 15, 2017
腫瘍崩壊症候群の高尿酸血症に対するキサンチンオキシダーゼ阻害薬の薬効評価

簔原豪人, 真家紘一郎, 小原直, 千葉滋, 木村耕二, 山田安彦, 本間真人, 本間真人

臨床薬理, 48(Suppl.) S288-S288, Nov, 2017
Anti-TNFのTDMはIBDのValue-based Medicineに有益か?

吉田篤史, 木村耕二, 森實敏夫, 原真太郎, 白井真如紀, 森川吉英, 遠藤豊, 上野文昭, 山田安彦

日本消化器病学会雑誌, 114(臨増大会) A803-A803, Sep, 2017
IL‐6受容体遺伝子多型がトシリズマブの標的であるIL‐6受容体の発現量に与える影響に関する検討

木村耕二, 鈴木賀子, 高柳理早, 山田安彦

医療薬学フォーラム講演要旨集, 25th 219, Jun, 2017
医薬品情報解析に基づいたオマリズマブの適切な投与設計法の開発

木村耕二, 山下裕太郎, 高柳理早, 山田安彦

日本医薬品情報学会総会・学術大会講演要旨集, 20th 179, Jun, 2017
副作用の発見及び重篤化回避に対する薬剤師の介入効果とその解析

今浦将治, 山谷武司, 上原望, 眞野匠智, 永瀬怜司, 木村耕二, 菅野浩, 山田安彦

薬学雑誌, 137(6) 767-774, Jun, 2017
クローン病に対するアダリムマブの抗炎症効果の解析

木村耕二, 高柳理早, 山田安彦

日本医療薬学会年会講演要旨集(Web), 27, 2017
がん化学療法に伴う高尿酸血症に対するラスブリカーゼの母集団薬力学解析

木村耕二, 簑原豪人, 本間真人, 山田安彦

日本薬学会年会要旨集(CD-ROM), 137th ROMBUNNO.27PB‐am230, 2017
スガマデクスの治療効果の予測に関する検討

木村耕二, 大村和也, 星野哲也, 高橋宏行, 今浦将治, 山田安彦

臨床薬理, 47(Supplement) S254, Oct 31, 2016
日本と米国における常用量の相違に関する理論的評価

高柳理早, 遠藤祐喜, 木村耕二, 山田安彦

臨床薬理, 47(Supplement) S280, Oct 31, 2016
FCGR3A遺伝子158V/F多型がアダリムマブのADCC活性に与える影響に関する検討

木村耕二, 山本瑞貴, 鳩山紗緒里, 山田安彦

医療薬学フォーラム講演要旨集, 24th 209, Jun, 2016
関節リウマチ治療薬トファシチニブクエン酸塩の有効性および安全性に関する検討

木村耕二, 江原菜々花, 高柳理早, 山田安彦

日本医薬品情報学会総会・学術大会講演要旨集, 19th 149, May, 2016
腫瘍崩壊症候群の高尿酸血症に対するキサンチンオキシダーゼ阻害薬の薬効評価

簑原豪人, 簑原豪人, 真家紘一郎, 小原直, 千葉滋, 木村耕二, 山田安彦, 久賀圭祐, 本間真人

日本薬学会年会要旨集(CD-ROM), 136年会(4) 144-144, Mar, 2016
日本人におけるFCGR3A遺伝子‐158V/F多型の頻度解析

木村耕二, 小林大悟, 横山晴子, 高柳理早, 山田安彦

日本医療薬学会年会講演要旨集, 25th 333-333, Oct 23, 2015

Profile Information

Research Interests

Research Areas

Research History

Education

Awards

Papers

Misc.

Professional Memberships

Menu

Coauthors